Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Velocity-Loss Training and Parkinson's Disease

25 september 2026 bijgewerkt door: Joseph Signorile, University of Miami

Comparison of Neuromuscular and Functional Adaptations to 10% and 30% Velocity-Loss Threshold Resistance Training in Persons With Parkinson's Disease

This study will compare the effects of velocity-loss resistance training at 10% and 30% velocity loss thresholds on measures of muscle strength and power and tests of daily performance in older adults with Parkinson's disease.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Florida
      • Coral Gables, Florida, Verenigde Staten, 33147
        • Werving
        • Laboratory of Neruomuscular Research and Active Aging
        • Contact:
        • Hoofdonderzoeker:
          • Joseph Signorile, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

50 jaar tot 85 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Parkinson's Disease Hoehn & Yahr Stages 1-3
  • Able to walk 50 meters unassisted
  • Able to understand and communicate in English

Exclusion Criteria:

  • Uncontrolled cardiovascular or other neuromuscular disease that prevent participation in a training program
  • Any systemic inflammatory or autoimmune conditions such as rheumatoid arthritis, or other serious concomitant medical illness
  • Unresolved injury or surgery to the upper or lower limbs that prevents weight training.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: 10% Velocity-Loss Threshold Resistance Training

Participants will receive velocity-based resistance training at 10% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.

Participants will receive a total of twenty-four 45-minutes in-person training sessions at 10% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.

Experimenteel: 30% Velocity-Loss Threshold Resistance Training

Participants will receive velocity-based resistance training at 30% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.

Participants will receive a total of twenty-four 45-minutes in-person training sessions at 30% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in neuromuscular performance as measured by 1-repetition maximum (1RM)
Tijdsspanne: Baseline, 12 weeks

Maximal load that can be lifted in one repetition (1RM) will be assessed in both leg press and chest press exercises. The loads on the testing equipment will be increased across 5 to 7 testing repetitions. The persons 1RM will be the highest load the person can move through the range of motion of the exercise. There are no minimum or maximum scores for this test. The higher the 1RM the stronger the person is. The unit of measurement is kilograms.

Baseline, 12 weeks
Change in neuromuscular performance as measured by Watts
Tijdsspanne: Baseline, 12 weeks

This test measures the power a person can produce at maximal speed using loads of 20%, 40%, 60%, 80%, and 90% of 1RM for the chest press and leg press. Power shows how fast a person can do work. There are no minimum or maximum possible values. Higher values indicate better neuromuscular performance. Unit of measure is Watts.

Baseline, 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in the Speed of the Ten-Meter Walk Test.
Tijdsspanne: Baseline, 12 weeks

The ten-meter walk test will be used to assess gait velocity. The participants will be asked to walk at usual walking speed and as quickly as possible in a straight line on a 10-meter (m) course marked at 0, 2, 8 and 10 m. On verbal command, participants will start on the 0-m mark and stop when the 10-m mark is crossed. The total time to ambulate from the 2-m mark to the 8-m mark (6 m total) will be timed to the hundredth of a second. Two trials will be performed at each speed, and the average will be documented in meters per second. One-minute recoveries will be provided between trials.

Baseline, 12 weeks
Change in Time for the Five Times Sit-to-Stand Test.
Tijdsspanne: Baseline, 12 weeks

The five-time sit-to-stand test will be used to assess functional lower body strength. The participant will sit with arms folded across the chest and the back against the chair. On a verbal command, the participant will stand up and sit down five times as quickly as possible. Timing begins at the word go and ends when the buttocks touch the chair after the fifth repetition. One practice and two testing trials will be performed. Time will be measured in seconds.

Baseline, 12 weeks
Change in the time required to complete the timed Up-and-Go Test.
Tijdsspanne: Baseline, 12 weeks

Upon verbal cue, participants will stand up, walk around a cone placed three meters from the front edge of the chair and then returns to a seated position as quickly as possible. Time is measured in seconds.

Baseline, 12 weeks
Change in Distance of the Seated Medicine Ball Throw.
Tijdsspanne: Baseline, 12 weeks

Upper body power will be assessed using the Seated Medicine Ball Throw test. Participants will sit in an armless chair with their back against the chair back and throw a 6-pound medicine ball from the chest as far as possible at an approximate 45-degree angle. Participants will complete three recorded test attempts. The distance thrown in meters will be measured. There are no minimum or maximum possible values. Greater throwing distances indicate better upper body power.

Baseline, 12 weeks
Change in Muscle Thickness using Ultrasound.
Tijdsspanne: Baseline, 12 weeks

Muscle thickness will be assessed using B-mode ultrasonography. Three longitudinal-view images will be obtained for each muscle assessed. Muscle thickness will be measured by drawing a perpendicular line from the superficial aponeurosis to the deep aponeurosis at the thickest region of the muscle. Assessments will be performed on selected thigh and upper arm muscles. Muscle thickness is measured in centimeters (cm). Higher values indicate greater muscle thickness.

Baseline, 12 weeks
Change in Muscle Quality using Ultrasound.
Tijdsspanne: Baseline, 12 weeks

Muscle quality will be measured using a gray scale. Grayscale values range from 0 to 255 units, where lower values (darker pixels) indicate greater muscle tissue content and higher values (lighter pixels) indicate greater intramuscular fat. The muscle to be tested will be the thigh muscles and the back of your arm. Lower grayscale values indicate better muscle quality.

Baseline, 12 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Joseph F. Signorile, PhD, University of Miami - Coral Gables Campus

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 september 2026

Primaire voltooiing (Geschat)

30 december 2026

Studie voltooiing (Geschat)

30 december 2026

Studieregistratiedata

Eerst ingediend

18 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 september 2026

Eerst geplaatst (Werkelijk)

25 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 20260975

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren